KEY DETAILS
A McGill-sponsored Phase 2/3 trial (NCT07891156) is recruiting about 40 adults with type 1 diabetes and overweight or obesity to compare semaglutide with a placebo.
A medRxiv preprint dated October 23, 2026, which has not been peer reviewed, found GLP-1 receptor agonists may reduce alcohol consumption and cigarettes smoked per day, with the clearest evidence for semaglutide.
A cohort study published October 22, 2026 linked sustained GLP-1 receptor agonist exposure to greater improvement in BMI and HbA1c categories and a lower incidence of diabetes in older adults with obesity and without diabetes.
Three GLP-1 research items dated October 22 and 23, 2026 cover a clinical trial recruiting for type 1 diabetes, an early look at alcohol and tobacco use, and a study on long-term use in older adults. If you take a GLP-1 or are considering one, these findings touch on different areas, from body composition to blood sugar to habits like drinking and smoking. None of them are final answers. Here is what each one reports, and what it does not yet tell us.
This one is still gathering its participants. A Phase 2/3 trial sponsored by McGill University Health Centre, registered as NCT07891156, is recruiting about 40 adults with type 1 diabetes and overweight or obesity to compare semaglutide against a placebo. It runs for 24 weeks, with participants self-administering the treatment once a week and attending a remote follow-up visit four weeks after treatment ends. The goal is to learn how semaglutide affects body composition in this group compared with placebo. Its listed start date is October 13, 2026 and its listed completion date is October 1, 2028. It is still recruiting, so there are no results yet.
This one comes with a caveat right in its description. A medRxiv preprint, a systematic review and meta-analysis of randomised controlled trials on GLP-1 receptor agonists for tobacco and alcohol dependence, has not been peer reviewed. It reports that GLP-1 receptor agonists may reduce alcohol consumption and cigarettes smoked per day, with the clearest evidence for semaglutide. The authors note that most of the evidence is low to very low certainty, so it is an early signal rather than a settled finding.
This study looked at what happens when people stay on these medications longer. A cohort study published in Diabetes, Obesity and Metabolism, dated October 22, 2026, compared older adults with obesity and without diabetes who had sustained GLP-1 receptor agonist exposure with those who had minimal exposure. Sustained exposure was associated with greater improvement in BMI and HbA1c categories and a lower incidence of diabetes. The findings describe observed changes after treatment initiation, not a proven causal treatment effect.
That is three different angles on where GLP-1 research stands. Each full entry, with its source and its own caveats, is available on glp1laws.com.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.